Materials were obtained from the following sources: serum-free medium (OptiMEM-I), Dulbecco phosphate-buffered saline (PBS), gentamicin, and trypsin-EDTA (Gibco BRL/Life Technologies, Rockville, MD); mouse submaxillary gland nerve growth factor and bovine pituitary extract (Biomedical Technologies, Stoughton, MA); mouse submaxillary gland epidermal growth factor (Upstate Biotechnologies, Lake Placid, NY); fetal bovine serum (FBS; Hyclone, Logan, UT); ascorbic acid, chondroitin sulfate, calcium chloride, 0.02% ethylene diamine tetraacetic acid (EDTA) solution, dimethyl sulfoxide (DMSO), and antibiotic/antimycotic solution (Sigma, St. Louis, MO); cell attachment reagent (FNC Coating Mix; Biological Research Faculty and Facility, Ijamsville, MD); mouse monoclonal antibody to the α1 chain of bovine collagen VIII (Seikagaku America, East Falmouth, MA); rabbit polyclonal antibody to the α2 chain of bovine collagen VIII (gift of Paul F. Davis,
18 Wellington, New Zealand); rabbit polyclonal antibody to ZO-1 (Zymed Laboratories, Inc., South San Francisco, CA); Cy-3–conjugated donkey anti–rabbit secondary antibodies (Jackson ImmunoResearch, West Grove, PA); Hoechst nuclear staining (Molecular Probes, Eugene, OR); and eight-well glass chamber slides (Laboratory-Tek, Nunc, Rochester, NY). High-titer (5 × 10
8to 1 × 10
9 transducing (T) U/mL) preparations of EIAV pseudotyped with a vesicular stomatitis virus (EIAV-VSVG) or with rabies virus (EIAV-rabies) envelope protein with the cytomegalovirus (CMV) promoter driving marker gene enhanced green fluorescent protein (eGFP) expression were obtained from Oxford BioMedica (Oxford, UK).
26